Mitapivat, a novel experimental agent, represents a promising advancement in the treatment of erythroid disorders such as pyruvate kinase deficiency (PKD). This unique molecule functions as a potent protein kinase R, boosting its activity and, consequently, improving erythropoiesis. Its function is believed to correct metabolic abnormalities associ